Sitagliptin and Acute Pancreatitis: Cases and Literature Review

2012

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.5336/medsci.2010-20920
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Acute pancreatitis is the rapid onset inflammation of the pancreas. Medications are rare but important and rising cause of acute pancreatitis and account for approximately 2% of all cases. Sitagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of patients with type 2 diabetes mellitus and acts by increasing active incretin hormone concentrations. Adverse effects including constipation, nausea, nasopharyngitis, urinary tract infection and dizziness were reported. We reported a case with acute pancreatitis that seems to be induced by sitagliptin.